

PPLICANT(S): Gordon Duane HOLT et al.

SERIAL NO.: 10/601,837

EXAMINER: Unknown

DATE FILED: June 23, 2003

ART UNIT: 1645

FOR: PROTEINS, GENES AND THEIR USE FOR DIAGNOSIS AND

TREATMENT OF KIDNEY DISEASE

CERTIFICATE OF MAILING UNDER 37 CFR §1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Commissioner For Patents, P.O. Box 1450, Alexandria, VA on October 18, 2003.

(Name of depositor)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

In accordance with Applicant's and Applicant's representatives' Duty of Disclosure under 37 CFR § 1.56, and pursuant to 37 CFR §1.97 and MPEP 717.05(b), Applicant(s) submit herewith documentary information for consideration by the Examiner. Information herein cited is only set forth in fulfillment of Applicant's duty of candor in disclosing all information brought to his attention, and is not an admission that it can be used adversely. The publications forwarded herewith are listed on the enclosed Form PTO-1449. Applicant(s) request that the Examiner, upon reviewing the enclosed materials, initial the enclosed form and return a copy thereof in accordance with the instructions on the form.

Enclosed please find copies of References **BA** through **CF** listed on the attached Form PTO-1449. No fee is believed due for the filing of this statement inasmuch as it is being filed before the mailing of the first official action on the merits. However, should the Patent and Trademark Office determine otherwise, authorization is hereby given to charge Deposit Account No. 11-1153 for this filing.

Respectfully submitted,

David A. Jackson

Attorney for Applicants Registration No. 26,742

KLAUBER & JACKSON 411 Hackensack Avenue Hackensack, New Jersey 07601 (201) 487-5800

2543-1-030 **ATTORNEY** Form PTO-1449 IRSY. 7.801 DOCKET U.S. Department of Commerce NO. Patent and Trademark Office 10/601,837 SERIAL NO. Gordon Duane HOLT et al. **APPLICANT** June 23, 2003 **FILING** DATE

GROUP

1645

IST OF DOCUMENTARY INFORMATION CITED BY APPLICANT

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

	U.S. PATENT	DOCOMENT			
DOCUMENT NUMBER	DATE	NAME	CLAS S	SUB- CLASS	FILING DATE IF APPROPRIATE
1,0,1,0					
	DOCUMENT NUMBER	DOCUMENT DATE	DOCUMENT DATE NAME	DOCUMENT DATE TO THE	DOCUMENT DATE NAME CLAS SUB-

FOREIGN PATENT DOCUMENTS

-	DOCUMENT	DATE	COUNTRY	CLAS	SUB-	TRANSLATION
	NUMBER			s	CLASS	YES NO
ВА	WO 99/47925	9/23/99	PCT			
1.7						

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

U	THEN PRIOR ALT (Meldaling Themes
CA	Kennedy, S., Proteomic profiling from human samples: the body fluid alternative, Toxicology Letters 120 (2001), Pgs. 379-384.
СВ	Cutler, P., et al., An integrated proteomic approach to studying glomerular nephrotoxicity, Electrophoresis (1999), 20, Pgs. 3647-3658.
СС	Witzmann, F., et al., Regional protein alterations in rat kidneys induced by lead exposure, Electrophoresis (1999), 20, Pgs.943-951.
CD	Kanitz, MH., et al., Alterations in rabbit kidney protein expression following lead exposure as analyzed by two-dimensional gel electrophoresis, Electrophoresis (1999), 20, Pgs.2977-2985.
CE	Ho, Y-W., et al., Activation and Inhibition of Human Alcohol Dehydrogenase by Monoclona Antibodies, Biochimica et Bioophysica Acta (1991), 1074, Pgs. 419-423
CF	Manabe, T., et al., A nondenaturing protein map of human plasma proteins correlated with a denaturing polypeptide map combining techniques of micro two-dimensionalgel electrophoresis, Electrophoresis (1999), 20, Pgs. 830-835.
	DATE CONSIDERED:

EXAMINER:

DATE CONSIDERED:

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.